Recent Blog Posts

View Post: Patent Docs: Court Report
15 Nov 2009 by Patent Docs  
... 2008) following a Paragraph IV certification as part of Alcon's filing of an ANDA to manufacture a generic version of Allergan's Combigan® (brimonidine tartrate/timolol maleate ophthalmic solution, used to treat glaucoma). ...
View Blog: Patent Docs - http://www.patentdocs.org/

---

View Post: Allergan Announces Victory in Brimonidine Patent Infringement Case ...
25 Oct 2009
("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in ... ALPHAGAN® P 0.1% and 0.15% are indicated for lowering elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. ALPHAGAN® P 0.1% and 0.15% are contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. ...
View Blog: Pharmaceutical Events (November-2009) - http://www.pharmiweb.com/

---

View Post: Allergan, Inc. Receives FDA Approval for Combigan (brimonidine ...
31 Oct 2007
Combigan is the newest addition to Allergan's comprehensive glaucoma portfolio, which also includes Lumigan (bimatoprost ophthalmic solution) 0.03% and Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. ...
View Blog: Drugs.com - New Drug Approvals - http://www.drugs.com/newdrugs.html

---

View Post: Alphagan-P (Brimonidine Tartrate) Drug Information: Uses, Side ...
3 Apr 2009
In a well-controlled clinical study conducted in pediatric glaucoma patients (ages 2 to 7 years) the most commonly observed adverse events with brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: Allergan's Combigan approved for glaucoma - Brimonidine/timolol ...
31 Oct 2007
Allergan has received an agency nod for its combination ophthalmic solution Combigan. The FDA approved the new product, which contains both brimonidine tartrate and timolol maleate, for the reduction of intraocular pressure (IOP) in ...
View Blog: Drug Topics - Drug Topics Daily News - http://www.drugtopics.com/drugtopics/Drug+Topics+Daily+New...

---

View Post: Allergan Reports Third Quarter 2009 Operating Results - Drugs.com ...
29 Oct 2009
On July 7, 2009, Senju Pharmaceutical Co., Ltd received approval from the Japanese Ministry of Health, Labour and Welfare for LUMIGAN™ Ophthalmic Solution 0.03% for the treatment of glaucoma or ocular hypertension. ... (collectively, the " Defendants") finding that the patents are valid and enforceable against the Defendants and that the Defendants' proposed generic versions of Allergan's ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% products ...
View Blog: Drugs.com - Pharma News - http://www.drugs.com/news.html

---

View Post: Lumigan X EU Committee Recomendation - GLG News
27 Oct 2009 by Andrew Dahl  
The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. ... Allergan's ill-advised manipulation of concentrations with their Alphagan (brimonidine) product by bringing out Alphagan-P did not take market share from its competitors within the glaucoma space. ...
View Blog: GLG News(sm): Healthcare - http://www.glgroup.com/Council-News-Listing/Healthcare-1.html

---

View Post: Aton Pharma acquires Timoptic product line - MPR
16 Mar 2009
The Timoptic product line includes Timoptic (timolol maleate) ophthalmic solution, Timoptic Ocudose (timolol maleate) ophthalmic solution in a sterile ophthalmic unit dose dispenser, and Timoptic-XE (timolol maleate) ophthalmic gel forming solution. ... Eye Disorders > Glaucoma. α2-AGONISTS: The α2-agonists (eg, brimonidine, apraclonidine) reduce aqueous humor production and increase uveoscleral outflow to lower intraocular pressure (IOP). By . ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: FDA Approvals: Combigan and Tasigna
8 Nov 2007
On October 30, the FDA approved brimonidine tartrate/timolol maleate 0.2%/0.5% topical ophthalmic solution ( Combigan; Allergan, Inc) to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require ...
View Blog: Medscape Ophthalmology Headlines - http://www.medscape.com/ophthalmology?src=rss

---

View Post: Recent advances in pharmacotherapy of glaucoma Gupta SK, Galpalli ...
21 Nov 2008 by Gupta SK, Galpalli Niranjan D, Agrawal...  
Brimonidine Brimonidine is the a-2 agonist of choice in glaucoma treatment, which acts by decreasing the aqueous humor secretion and increasing the uveoscleral outflow. It does not cross the blood-brain barrier and is 30 times more selective for the ... Timolol is the US-FDA's gold standard drug for glaucoma therapy, against which all new medications must be compared prior to approval. Carteolol Carteolol hydrochloride [Figure 4] ophthalmic solution, 1%, is a nonselective ...
View Blog: Table of Contents : Indian Journal of Pharmacol... - http://www.ijp-online.com/currentissue.asp

---